Patents by Inventor Yves Emiel M VAN ROOSBROECK

Yves Emiel M VAN ROOSBROECK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OGA INHIBITOR COMPOUNDS
    Publication number: 20230099293
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 30, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: José Manuel BARTOLOMÉ-NEBREDA, Petrus Jacobus Johannes Antonius BUIJNSTERS, Ana Isabel DE LUCAS OLIVARES, Joseph Elisabeth LEENAERTS, Carolina MARTINEZ LAMENCA, Daniel OEHLRICH, Andrés Avelino TRABANCO-SUÁREZ, Yves Emiel M VAN ROOSBROECK, Adriana Ingrid VELTER
  • OGA INHIBITOR COMPOUNDS
    Publication number: 20230058733
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: José Manuel BARTOLOMÉ-NEBREDA, Petrus Jacobus Johannes Antonius BUIJNSTERS, Joseph Elisabeth LEENAERTS, Carolina MARTINEZ LAMENCA, Daniel OEHLRICH, Andrés Avelino TRABANCO-SUÁREZ, Yves Emiel M VAN ROOSBROECK, Adriana Ingrid VELTER